SEC Form 4 · accession 0000950138-16-001493
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Trudeau
Officer — President and CEO · Director
Period of report
Dec 3, 2016
Accepted (ET)
Dec 6, 2016 · 8:24 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Dec 3, 2016 | F | 1,566 | $53.61 | D | 191,236 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 256 shares acquired on September 30, 2016 under the Mallinckrodt employee stock purchase plan.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.